In 2025, the company reported a -1.92% YoY revenue decline, reflecting portfolio shifts: Eliquis ($7.9B) remains a key anticoagulant franchise with steady demand, Prevnar family ($6.4B) continues to anchor its vaccines business despite some normalization, and Vyndaqel family ($6.38B) is rapidly growing in rare cardiomyopathy helping offset declines in other segments
However, keep reading to find more recommendations based on your individual skin type and concerns
These are the kinds of shifts that can reshape daily habits and long-term health trajectories without requiring dramatic physical changes
References Graybill S, Hatfield J, Kravchenko M, Beckman D, Tate J, Beauvais A, et al
Use this peptide calculator to eliminate that risk entirely